These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 19497209)

  • 21. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of lamivudine-resistant hepatitis B in HIV-infected persons: is adefovir dipivoxil the answer?
    Thio CL
    J Hepatol; 2006 Jan; 44(1):1-3. PubMed ID: 16293338
    [No Abstract]   [Full Text] [Related]  

  • 23. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B.
    Sung JJ; Lai JY; Zeuzem S; Chow WC; Heathcote EJ; Perrillo RP; Brosgart CL; Woessner MA; Scott SA; Gray DF; Gardner SD
    J Hepatol; 2008 May; 48(5):728-35. PubMed ID: 18329126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. De novo combination therapy adefovir plus lamivudine as a treatment for women of child-bearing age with HBeAg-positive chronic hepatitis B before pregnancy.
    Ma LN; Ding XC; Liu XY; Xu CQ; Liu SW; Yan X
    J Med Virol; 2014 Mar; 86(3):433-6. PubMed ID: 24166586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance of HBV to adefovir dipivoxil: a case for combination antiviral therapy?
    Aloman C; Wands JR
    Hepatology; 2003 Dec; 38(6):1584-7. PubMed ID: 14655682
    [No Abstract]   [Full Text] [Related]  

  • 29. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis.
    Liaw YF; Lee CM; Chien RN; Yeh CT
    J Viral Hepat; 2006 Apr; 13(4):250-5. PubMed ID: 16611191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B.
    Sato K; Takagi H; Kakizaki S; Sohara N; Mori M
    J Gastroenterol; 2006 Mar; 41(3):283-5. PubMed ID: 16699864
    [No Abstract]   [Full Text] [Related]  

  • 31. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir.
    Seto WK; Liu K; Fung J; Wong DK; Yuen JC; Hung IF; Lai CL; Yuen MF
    Antivir Ther; 2012; 17(7):1255-62. PubMed ID: 22951420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and virological effects during two years of ongoing adefovir dipivoxil in the treatment of lamivudine-resistant chronic hepatitis B infection.
    Gornals JB; Casanovas T; Sabidó M; Baliellas C; Casanovas A; Cañas C; Serrano T; Verdura B; Chahri N; Gil-Vernet S; Figueras J
    Transplant Proc; 2005 Nov; 37(9):3957-9. PubMed ID: 16386595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Lunghi G; Colombo M
    Hepatology; 2005 Dec; 42(6):1414-9. PubMed ID: 16317671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
    Tong MJ; Tu SS
    Semin Liver Dis; 2004; 24 Suppl 1():37-44. PubMed ID: 15192800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
    Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
    J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
    Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Du Jeong I; Bang SJ; Park NH
    Antivir Ther; 2012; 17(2):387-94. PubMed ID: 22293395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
    Ohkawa K; Takehara T; Kato M; Kanada A; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
    J Med Virol; 2009 May; 81(5):798-806. PubMed ID: 19319954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of chronic hepatitis B with primary adefovir resistance].
    Yamazhan T; Sertöz R; Pullukçu H; Taşbakan M; Ulusoy S; Erensoy S
    Mikrobiyol Bul; 2007 Apr; 41(2):297-301. PubMed ID: 17682718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.